Intercept Pharmaceuticals (ICPT)

[osaffer]

- Professor Stephen Harrison will detail the beneficial effects of Elafibranor (GFT505) on
cardiometabolic risk markers of NASH patients:
“BENEFICIAL EFFECTS OF THE DUAL PPAR ALPHA-DELTA AGONIST, GFT505, ON HEPATIC AND
CARDIOMETABOLIC MARKERS IN ADULT NASH PATIENTS” SA Harrison et al. (Abstract 162)
- Professor Arun Sanyal will analyze the hepatic and extra-hepatic responses linked to the
treatment of NASH by Elafibranor:
“THE HEPATIC AND EXTRA-HEPATIC PROFILE OF RESOLUTION OF STEATOHEPATITIS INDUCED
BY GFT-505” A Sanyal et al. (Abstract 2145)